ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to liquid biopsy at baseline). Patients have been treated in front lines with irinotecan and cetuximab and had a clinical benefit (complete or partial response) from both of them, no matter whether they had treated by any PD-1 inhibitor before.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony histologicznie rak jelita grubego z przerzutami
- •Określony typ nowotworu (RAS i BRAF wild-type potwierdzone badaniem krwi)
- •Wcześniejsza dobra odpowiedź na leczenie irynotekanem lub cetuximabem
- •Co najmniej 2 miesiące przerwy od ostatniej dawki cetuximabu z pierwszej linii leczenia
- •Mierzalne zmiany guza widoczne w badaniach obrazowych
- •Ogólny stan zdrowia pozwalający na uczestnictwo (ECOG 0-1)
- •Prawidłowe wyniki badań krwi, wątroby i nerek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Beijing Hospital
Beijing, China
Trial contact
Yingying Huang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.